WATER SOLUBLE POLYMER MICROSPHERES AS VACCINE VEHICLES

作为疫苗载体的水溶性聚合物微球

• 批准号: 2072175
• 负责人: LENDON G PAYNE
• 金额: $ 8.1万
• 依托单位: VIRUS RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-04-15 至 1994-10-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2072175
• 关键词: T lymphocyte; alginates; antibody formation; bacterial antigens; drug administration rate /duration; drug screening /evaluation; drug vehicle; enzyme linked immunosorbent assay; immunoglobulin G; influenza vaccines; influenzavirus A; inhalation drug administration; laboratory mouse; leukocyte activation /transformation; microcapsule; microorganism immunology; mucosa; oral administration; pharmacokinetics; plaque assay; polymers; tetanus toxoid; virus antigen; water solubility

The majority of viral vaccines establish a state of systemic protective immunity by injection of live attenuated or inactivated virus preparations. The use of injectable vaccines has reduced the incidence of many viral diseases. Nevertheless, their usage is associated with some undesirable side effects. Live attenuated virus vaccines can cause systemic complications; inactivated vaccines can have local reactogenicity and even induce an allergic state. An alternative to the use of injectable vaccines is the mucosal administration of non-replicating antigens. A major focus of the Virus Research Institute is the study of delivery vehicles. Microencapsulation is the core technology in this endeavor. The SBIR Phase I work goal is to develop microsphere configured vaccine vehicles based on the we water soluble polyphosphazenes. This goal will be accomplished by optimizing size and composition of microspheres and determining the dose and mucosal route of administration that maximize the rapidity, amplitude and duration of the antibody response to a single antigen dose. The distribution of the antibody response over the Ig isotypes, as well as over the IgG subclasses and the cellular immune response will be determined. Finally, the protective efficacy of the polymer microsphere immunization regimen in an animal model will be evaluated.

大多数病毒疫苗建立了系统性保护状态 通过注射活病毒或灭活病毒制剂的免疫力。 可注射疫苗的使用降低了许多病毒的发生率 疾病。 然而，它们的用法与一些不良的使用有关 副作用。 活病毒疫苗可引起全身性疫苗 并发症；灭活的疫苗可以具有局部反应性，甚至 诱导过敏状态。 使用可注射疫苗的替代方法是粘膜 给药非复制抗原。 病毒的主要重点 研究机构是对送货车辆的研究。 微囊性 是这项努力的核心技术。 SBIR I期工作目标是开发配置的微球疫苗 基于我们的水溶性多磷烯的车辆。 这个目标将是 通过优化微球的大小和组成而完成 确定最大化的剂量和粘膜给药途径 抗体反应的速度，幅度和持续时间 抗原剂量。 抗体反应在Ig上的分布 同种型以及IgG亚类和细胞免疫 将确定响应。 最后，保护性的效力 动物模型中的聚合物微球免疫方案将是 评估。